Curis (CRIS)
(Delayed Data from NSDQ)
$5.91 USD
-0.02 (-0.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.76 -0.15 (-2.54%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.91 USD
-0.02 (-0.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.76 -0.15 (-2.54%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Down 23.2% in 4 Weeks, Here's Why Curis (CRIS) Looks Ripe for a Turnaround
by Zacks Equity Research
Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 7.69% and 14.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Curis (CRIS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Curis (CRIS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 20th
by Zacks Equity Research
AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021
Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curis (CRIS) Surges: Stock Moves 5% Higher
by Zacks Equity Research
Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News
by Zacks Equity Research
Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
by Zacks Equity Research
Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.
Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CRIS) Outperforming Other Medical Stocks This Year?
Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CRIS) Outperforming Other Medical Stocks This Year?
Aduro BioTech (ADRO) Looks Good: Stock Adds 7.7% in Session
by Zacks Equity Research
Aduro BioTech (ADRO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
New Strong Buy Stocks for December 13th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Curis (CRIS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
Curis (CRIS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).
Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 36.59% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.
Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.